PHARMACOVIGILANCE

Every dose monitored. Every signal answered.

A 24×7 safety unit that captures, evaluates, and reports adverse events across 34 markets — protecting patients long after approval.

Pharmacovigilance control room
LIVE MONITORING
24×7
Case intake
1,842
ICSRs processed
< 24h
Serious case triage
100%
Regulatory on-time
0
Missed timelines
OUR COMMITMENT

"Safety is not a department. It is a discipline that every batch, every prescription, and every patient interaction is measured against."

— Dr. R. Ahmed, QPPV, Head of Pharmacovigilance
PV FRAMEWORK

Four pillars of our safety system.

STEP 01
Collect

Every intake channel unified into one safety database.

STEP 02
Assess

Medical review, causality, seriousness, expectedness.

STEP 03
Report

Expedited & periodic reporting to 34 health authorities.

STEP 04
Prevent

Signal detection, RMPs, label updates, communication.

PV specialists reviewing cases
INSIDE THE PV UNIT
14 trained safety physicians and pharmacists — reviewing cases the same day they arrive.
14
Specialists
4
MDs on staff
3
Shifts / day
HOW TO REPORT

Six ways to reach our safety desk.

Patients, caregivers, and healthcare professionals — anyone can report. All reports are confidential and reviewed within 24 hours.

24×7 Safety Hotline
+880 9666 700 700
Email
pv@company.com
WhatsApp
+880 1700 000 000
Online Form
Fill CIOMS-I web form
Field Force
Any medical representative
Prescriber Portal
Healthcare-professional login
CASE PROCESSING

From intake to expedited report.

1
Intake
Any channel
2
Duplicate check
Global DB
3
Medical review
Physician assessment
4
Coding
MedDRA + WHO-DD
5
QC
Peer review
6
Submission
E2B(R3) XML
REGULATORY TIMELINES

The clock we run against.

Case TypeRegulatory ClockInternal SLAStatus
Serious, unexpected (SUSAR)7 calendar days5 days On track
Serious, expected15 calendar days10 days On track
Non-serious90 days (periodic)30 days On track
Fatal / life-threatening7 days (initial), 8 days follow-up24 hours Critical
Special situations (pregnancy, misuse)15 calendar days10 days On track
SIGNAL DETECTION

Statistical vigilance, not just paperwork.

We run quantitative signal detection (PRR, ROR) across our case database every month, plus qualitative literature and label review.

  • PRR & ROR disproportionality analysis
  • Quarterly signal validation committee
  • Literature screening (Embase, PubMed) — weekly
  • Trigger for RMP updates & label changes
SIGNAL DASHBOARD · Q4 2026
142
Signals reviewed
6
Validated
2
Label updates
JanAprJulOctDec
QUALIFIED PERSON

Meet our QPPV.

QPPV portrait
Dr. Rezaul Ahmed, MBBS, MPH
Qualified Person for Pharmacovigilance (QPPV)

18 years in drug safety across South Asia and MENA. Certified by ISoP, former reviewer at DGDA drug safety cell. Available on-call, globally, for regulator inspections and urgent safety decisions.

ISoP-certifiedDGDA liaisonGVP Module I–XVI24×7 on-call
RISK MANAGEMENT

Every risk has a plan.

TIER
Routine

Standard labeling, package leaflets, and pharmacovigilance activities.

Example — Most established generics
TIER
Additional

HCP educational materials, patient alert cards, controlled distribution.

Example — Isotretinoin, methotrexate
TIER
Enhanced

Registries, PASS studies, restricted-access programs.

Example — New biologics, oncology
PERIODIC AGGREGATE REPORTS

The reports we author every cycle.

PSUR / PBRER
Every 6–12 months per product
DSUR
Annual for investigational products
Addendum to Clinical Overview
For renewals
PADER (US-format)
For US-licensed markets
Safety monitoring workstation
SAFETY DATABASE
Argus Safety Suite — 21 CFR Part 11 validated.
Every case is entered, coded, and locked in a validated safety database with full audit trail.
GLOBAL PV COVERAGE

Local safety representation, worldwide.

Bangladesh
In-house QPPV
MENA
Local Safety Officers in KSA, UAE
Africa
LSOs in Kenya, Nigeria, Ghana
SEA & CIS
PV partner network
Literature review
LITERATURE MONITORING

Weekly scans, global databases.

Embase, PubMed/Medline, and local scientific journals — screened weekly for adverse event mentions relevant to our portfolio.

Embase (full)
PubMed / Medline
Local BD journals
Cochrane reviews
PV TRAINING

Every employee is a safety officer.

All Staff

Annual awareness — how to recognize & report an AE.

1 hour / year
Field Force

Detailed training — CIOMS form, timelines, follow-up.

8 hours / year
PV Team

GVP modules, MedDRA coding, signal methodology.

40 hours / year
INSPECTIONS & AUDITS

Independently verified.

2026
DGDA PV inspection
Zero critical, 2 minor — all closed within 30 days.
2025
Internal audit — QPPV office
Full conformance; 3 recommendations implemented.
2025
WHO-PQ desk assessment
PV system judged adequate for prequalified products.
2024
PPB Kenya PV audit
Certificate of compliance issued.
FAQ

What patients & HCPs ask us.

Is my report anonymous?
Reporter identity is kept strictly confidential. Only the safety team accesses it; regulators receive de-identified case data.
Do I need to be sure the medicine caused the reaction?
No. Report any suspicion. Our medical reviewers assess causality.
What information should I include?
Patient age/sex (no name), product name & batch if possible, the reaction, and when it started.
How long does it take to hear back?
Acknowledgement within 24 hours. Medical follow-up within 5 working days if needed.
Can I report for someone else?
Yes — caregivers, family members, and HCPs are welcome to report on a patient's behalf.
Where does my report go?
Into our validated safety database, then to health authorities per regulatory timelines.
Safety team meeting
SPEAK TO OUR SAFETY DESK

A reaction to report? A safety question? We're on the line — 24×7.

Reporting takes 3 minutes and helps every future patient. Your report is confidential and reviewed by a physician on our team.